Lifesaving therapy offers hope for patients with advanced heart failure, serving as a bridge to heart transplantation or long-term therapy. WASHINGTON, Nov. 17, 2025 /PRNewswire/ -- MedStar Washington ...
When Dr. Robert Kormos, a cardiothoracic surgeon, began his career 30 years ago, he would dream of extending the lives of his patients who were often battling advanced heart failure. Now, as division ...
MOMENTUM 3 Study meets primary endpoint for short-term indication Results presented during late-breaking clinical trial session at the AHA Scientific Sessions MOMENTUM 3 Study data published in the ...
ORLANDO, FL—The latest-generation HeartMate left ventricular assist device has beat out its predecessor with results so promising that at least one observer is raising the question of whether it’s ...
ORLANDO -- The HeartMate 3 advantage appears durable to 2 years, with still no pump thrombosis requiring reoperation and fewer replacements or disabling strokes compared with the prior-generation ...
ABBOTT PARK, Ill., Dec. 17, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) has approved updated labeling for the company's HeartMate 3™ heart pump ...
A novel approach to removing excess fluid through the skin and a new strategy to prevent right ventricular failure after LVAD implantation are among the highlights of the January issue of the Journal ...
With approval, the HeartMate 3 System offers physicians in Europe the most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure ST.
PLEASANTON, Calif., /PRNewswire/ -- Thoratec Corporation, a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that its CE ...
Abbott Laboratories' HeartMate 3 heart pump for advanced heart failure kept more patients alive for two years with fewer incidents of stroke than the company's prior left ventricular assist device ...
CLEVELAND, OH — Researchers are warning about "unexpectedly" and "abruptly" increased rates of thrombosis with the HeartMate II (Thoratec) left ventricular assist device (LVAD) occurring early after ...